UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read moreWed, 25th Jul 2018 10:15
UK Shareholder Meetings Calendar - Next 7 Days
Read more(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.
Read morePositive Headline Reading For Latest Midatech MTD201 Study
Read moreMidatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price
Read moreMidatech Pharma Gets EU Grant For Brain Cancer Drug
Read moreArmistice Capital Takes Almost 10% Interest In Midatech Pharma
Read moreMidatech Pharma Childhood Cancer Drug Given FDA Orphan Designation
Read moreMidatech Pharma Inks USD3.0 Million Registered Direct Offering Deal
Read moreMidatech Doses First Patients In MTD201 Administration Method Study
Read more(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.
Read moreDIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares
Read moreDIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares
Read moreMidatech Pharma Slims Interim Loss As Cancer Treatments Progress
Read moreMidatech Pharma Applies To US Regulator For Share Issue Authority
Read more(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).
Read more